Press Releases

March 12, 2019 at 1:34 PM EDT
Altimmune Announces Closing of $14 Million Registered Direct Offering
GAITHERSBURG, Md. , March 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct offering of common units and pre-funded units receiving gross proceeds of $14 million .
March 8, 2019 at 9:29 AM EST
Altimmune Announces $14 million Registered Direct Offering
GAITHERSBURG, Md. , March 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with two institutional investors for the purchase of common units and pre-funded units for a combined total of
Displaying 11 - 13 of 13

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe